Lotus Pharmaceutical Announces Completion of UroVaxom® Product Rights Acquisition in South Korea

Taipei, Taiwan, and Seoul, South Korea, 07 October 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced the completion of the acquisition of the South Korea product rights for UroVaxom® from OM Pharma, a global biopharmaceutical company headquartered in Geneva, Switzerland, following the successful transfer of the product’s marketing authorisation to its wholly owned subsidiary, Alvogen Korea.

Alvogen Korea is now the marketing authorisation holder for UroVaxom® in South Korea, having assumed responsibility for the product’s distribution on 1 July 2026¹ under the agreement announced in May 2026.2

UroVaxom® has an established clinical profile and long-standing market presence as an oral immunostimulant product for the prevention of recurrent urinary tract infections. The product is marketed in more than 53 countries and reached more than one million patients globally in 2025.

The completed acquisition further strengthens Lotus’ specialty portfolio in urology and infectious disease prevention, while expanding the Group’s portfolio of differentiated branded medicines in South Korea, one of its key Asian markets.

Petar Vazharov, Chief Executive Officer of Lotus, commented, “The transfer of the marketing authorisation completes our acquisition of the South Korea product rights for UroVaxom®. As the marketing authorisation holder, Alvogen Korea is well positioned to further expand the availability of UroVaxom®, supporting broader patient access to this important product. Looking ahead, we plan to initiate technology transfer and work towards bringing manufacturing in-house, supporting improved operational efficiency, plant utilisation and product economics over time.”

UroVaxom® is a registered trademark. All other trademarks are the property of their respective owners.

¹ https://www.lotuspharm.com/en/newsroom/news-page/328

2 https://www.lotuspharm.com/en/newsroom/news-page/323

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.

OM Pharma transforms immune health with bacterial lysates-innovative therapies that train and strengthen the body’s natural defenses. By prioritising prevention, the company helps reduce infections and protect vulnerable populations. Headquartered in Geneva, where its biotech site is also based, OM Pharma’s products are available in 100 countries and reach 16 million people globally through a trusted network of partners and affiliates. www.ompharma.com